Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

July 8th 2021

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

July 8th 2021

Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.

Rapid Readouts: Updated Results From the Phase 3 SIMPLIFY-1 Trial

July 8th 2021

Jean-Jacques Kiladjian, MD, PhD, describes updated results presented at the European Hematology Association 2021 Virtual Congress from the phase 3 SIMPLIFY-1 trial of momelotinib vs ruxolitinib in JAK inhibitor–naïve patients with myelofibrosis.

Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

July 8th 2021

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Rapid Readouts: SIMPLIFY-1 and SIMPLIFY-2 Trials

July 8th 2021

Ruben Mesa, MD, Director of UT Health San Antonio MD Anderson Cancer Center, presents data from the 2021 European Hematology Association Virtual Congress from the SIMPLIFY-1 and SIMPLIFY-2 trials of patients with myelofibrosis who were treated with momelotinib.

OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

July 8th 2021

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.

Dr. Wong on Treatment Goals in Systemic Amyloidosis

July 7th 2021

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

The Potential Future Impact of CAR T Cell Therapy in Adult ALL

July 7th 2021

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

The ZUMA-3 Trial: Clinical Endpoints

July 7th 2021

Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.

The ZUMA-3 Trial: Efficacy and Safety Results

July 7th 2021

Primary investigator Bijal Shah, MD, MS, shares insights into the efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and Eunice Wang, MD, reviews the trial’s key safety data.

The ZUMA-3 Trial: Study Design and Patient Population

July 7th 2021

Leukemia experts provide an overview of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) by discussing the overall study design and patient population.

Monitoring Disease Response or Progression in MF

July 6th 2021

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Recent Updates to NCCN Guidelines on MF Treatment

July 6th 2021

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Phase 3 ARMADA 2000 Trial of Devimistat in Relapsed/Refractory AML to Continue

July 2nd 2021

An independent data monitoring committee has recommended that the phase 3 ARMADA 200 trial examining devimistat plus high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia continue as planned.

FDA Approves Rylaze for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

June 30th 2021

The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regimen to treat pediatric and adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products.

Dr. Adams on Tackling Storage and Logistical Challenges in Cell Therapy

June 30th 2021

Julian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.

Menin Inhibitors Like KO-539 May Represent Next Forefront of AML Treatment

June 30th 2021

Eunice Wang, MD, discusses the KOMET-001 trial, the potential for KO-539 to address an unmet need in acute myeloid leukemia, and the future of menin inhibition in this disease.

Dr. Adams on Improving Bone Marrow Transplant With Omidubicel

June 30th 2021

Julian Adams, PhD, discusses approaches to cell therapy, and the potential of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.

Using MRD to Monitor Therapeutic Response in ALL

June 30th 2021

Key experts in hematology oncology discuss the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.

The Evolving Treatment Landscape for ALL

June 30th 2021

Eunice Wang, MD and Bijal Shah, MD, MS, begin with an overview of novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.